Clinical Trial Search

Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…

Primary: Number of Participants With the First Occurrence of New or Worsening Stromal Keratitis Without Ulceration (SK), Endothelial Keratitis (EK), Iritis (IR), Dendriform…

Primary: Change in Cell Mediated Immunity — 33; 33; 33; 50 cells per million — p=0.16

Primary: Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination — 0; 0; 100; 101 Participants

Primary: Evaluation of Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) Related Direct Medical Costs by Drugs Prescribed. — 10; 1; 3; 0 Participants

Primary: Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender — 5.19; 6.29; 5.00; 9.19 Number of HZ cases/1000 person-years

Primary: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA — 74; 26; 26; 22 Participants

Primary: Change in Innate Immune Signatures Post-vaccine Dose — 1.6801; 2.096; -0.5609; -1.1284 Normalized Enrichment Score (NES)

Primary: The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment — 69.6; 81.1; 75.1 percentage of Participants — p=0.00000241

Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample

Primary: Incidence of Confirmed Herpes-Zoster — 32.889; 91.883 Number of cases per 1000 person years

Primary: Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells — 726.19; 567.52 cells/million T-cells

Primary: Answers to Survey Questions — 89; 71.2; 98; 74 Percentage of responders

Primary: Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood — 0.02 percentage of CD4 T cells

Primary: Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE) — 85.7; 7.8 Percentage of participants

Primary: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV — 45; 9 Participants

Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 8.2 Cases per 1000 person-years — p=<0.0001

Primary: GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at…

Primary: Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers — 1801.23; 1722.83; 1778.48…

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 25; 19; 22; 4 Participants

Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Cases — 3; 2; 1; 6 Participants — p=<0.0001

Primary: Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX — 44; 33 participants

Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 4.1 Cases per 1000 person-years

Primary: Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations — 9122.9 mIU/mL

Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode — 49; 135 Participants — p=<0.0001

Primary: Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody — 2.8 Ratio

Primary: Anti-glycoprotein E (Anti-gE) Antibody Concentrations, as Assessed in the Long Term Follow-up (LTFU) Phase of the Current ZOSTER-073 Study — 3729.8; 3440.2; 3075.8 mIU/mL

Primary: Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses — 553.5; 588.7 gpELISA units/mL

Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 1.57 Ratio — p=<0.0001

Primary: Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly — 50.17; 78.17; 83.22; 120.56 Spot Forming Units per 10^6 PBMC